Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1Temporarily not available 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Sarcoma 4Thoracic 1Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 7Ovarian Neoplasms 6Lung Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Sarcoma, Ewing 4Leukemia 4Uterine Neoplasms 3Uterine Cervical Neoplasms 3Neoplasms 3Multiple Myeloma 3Kidney Neoplasms 3Gliosarcoma 3Glioblastoma 3Central Nervous System Neoplasms 3Carcinoma, Renal Cell 3Astrocytoma 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma, Follicular 2Lymphoma 2Fallopian Tube Neoplasms 2Congenital Abnormalities 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Brain Neoplasms 2Thymoma 1Small Cell Lung Carcinoma 1

Interventions

Cyclophosphamide 25Temozolomide 22Vincristine 18Irinotecan 18Doxorubicin 13Topotecan 10Melphalan 10Etoposide 10Ifosfamide 8Busulfan 8cabozantinib 7Magnetic Resonance Spectroscopy 7Granulocyte Colony-Stimulating Factor 7Filgrastim 6regorafenib 5fludarabine 5X-Rays 5Specimen Handling 5Sirolimus 5Radiotherapy 5Gemcitabine 5Drug Therapy 5pegfilgrastim 4palbociclib 4liposomal doxorubicin 4irinotecan sucrosofate 4ganitumab 4fludarabine phosphate 4Trabectedin 4Phantoms, Imaging 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Sarcoma, Ewing × FANG vaccine × Clear all
NCT03842865 2025-06-05

Expanded Access of Vigil in Solid Tumors

Gradalis, Inc.

Temporarily not available
GynecologicSarcoma

Uterine Cervical Neoplasms, Ovarian Neoplasms, Sarcoma, Ewing, Uterine Neoplasms

NCT03495921 2023-04-26

VITA

Gradalis, Inc.

Phase 3 Terminated
32 enrolled 13 charts
Sarcoma

Neoplasms, Neoplasms by Histologic Type, Neoplasms, Connective Tissue, Sarcoma, Sarcoma, Ewing, Neoplasms, Connective and Soft Tissue, Neoplasms, Bone Tissue, Neuroectodermal Tumors, Primitive, Peripheral, Rare Diseases

NCT02511132 2022-12-22

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Gradalis, Inc.

Phase 2 Completed
22 enrolled 13 charts
Sarcoma

Sarcoma, Sarcoma, Ewing

NCT01061840 2022-03-15

Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Gradalis, Inc.

Phase 1 Completed
100 enrolled
GastrointestinalSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡